Historical Valuation
NewAmsterdam Pharma Company NV (NAMS) is now in the Fair zone, suggesting that its current forward PS ratio of 1373.80 is considered Fairly compared with the five-year average of 1.14. The fair price of NewAmsterdam Pharma Company NV (NAMS) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：34.37
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
NewAmsterdam Pharma Company NV (NAMS) has a current Price-to-Book (P/B) ratio of 5.47. Compared to its 3-year average P/B ratio of 3.75 , the current P/B ratio is approximately 45.76% higher. Relative to its 5-year average P/B ratio of 0.87, the current P/B ratio is about 528.42% higher. NewAmsterdam Pharma Company NV (NAMS) has a Forward Free Cash Flow (FCF) yield of approximately -3.62%. Compared to its 3-year average FCF yield of -5.81%, the current FCF yield is approximately -37.71% lower. Relative to its 5-year average FCF yield of -5.69% , the current FCF yield is about -36.31% lower.
P/B
Median3y
3.75
Median5y
0.87
FCF Yield
Median3y
-5.81
Median5y
-5.69
Competitors Valuation Multiple
AI Analysis for NAMS
The average P/S ratio for NAMS competitors is 231.52, providing a benchmark for relative valuation. NewAmsterdam Pharma Company NV Corp (NAMS.O) exhibits a P/S ratio of 1373.80, which is 493.38% above the industry average. Given its robust revenue growth of -98.80%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for NAMS
1Y
3Y
5Y
Market capitalization of NAMS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NAMS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is NAMS currently overvalued or undervalued?
NewAmsterdam Pharma Company NV (NAMS) is now in the Fair zone, suggesting that its current forward PS ratio of 1373.80 is considered Fairly compared with the five-year average of 1.14. The fair price of NewAmsterdam Pharma Company NV (NAMS) is between to according to relative valuation methord.
What is NewAmsterdam Pharma Company NV (NAMS) fair value?
NAMS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of NewAmsterdam Pharma Company NV (NAMS) is between to according to relative valuation methord.
How does NAMS's valuation metrics compare to the industry average?
The average P/S ratio for NAMS's competitors is 231.52, providing a benchmark for relative valuation. NewAmsterdam Pharma Company NV Corp (NAMS) exhibits a P/S ratio of 1373.80, which is 493.38% above the industry average. Given its robust revenue growth of -98.80%, this premium appears unsustainable.
What is the current P/B ratio for NewAmsterdam Pharma Company NV (NAMS) as of Jan 10 2026?
As of Jan 10 2026, NewAmsterdam Pharma Company NV (NAMS) has a P/B ratio of 5.47. This indicates that the market values NAMS at 5.47 times its book value.
What is the current FCF Yield for NewAmsterdam Pharma Company NV (NAMS) as of Jan 10 2026?
As of Jan 10 2026, NewAmsterdam Pharma Company NV (NAMS) has a FCF Yield of -3.62%. This means that for every dollar of NewAmsterdam Pharma Company NV’s market capitalization, the company generates -3.62 cents in free cash flow.
What is the current Forward P/E ratio for NewAmsterdam Pharma Company NV (NAMS) as of Jan 10 2026?
As of Jan 10 2026, NewAmsterdam Pharma Company NV (NAMS) has a Forward P/E ratio of -19.47. This means the market is willing to pay $-19.47 for every dollar of NewAmsterdam Pharma Company NV’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for NewAmsterdam Pharma Company NV (NAMS) as of Jan 10 2026?
As of Jan 10 2026, NewAmsterdam Pharma Company NV (NAMS) has a Forward P/S ratio of 1373.80. This means the market is valuing NAMS at $1373.80 for every dollar of expected revenue over the next 12 months.